Journey Advisory Group LLC Raises Stake in Danaher Corporation $DHR

Key Points

• Journey Advisory Group LLC significantly increased its ownership in Danaher Corporation by 869.6%, acquiring a total of 14,544 shares valued at approximately $2.87 million.
• Danaher recently announced a quarterly dividend of $0.32 per share, with the ex-dividend date set for September 26th, reflecting an annualized yield of 0.6%.
• Several analysts have raised their price targets for Danaher, with a consensus target of $245.00 and a majority rating the stock as a "Moderate Buy."

Journey Advisory Group LLC grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 869.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,544 shares of the conglomerate's stock after purchasing an additional 13,044 shares during the period. Journey Advisory Group LLC's holdings in Danaher were worth $2,873,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in DHR. Nuveen LLC purchased a new stake in shares of Danaher during the 1st quarter worth $833,941,000. Invesco Ltd. boosted its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after buying an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after buying an additional 722,636 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 11.20% of the stock is currently owned by corporate insiders.

Danaher Price Performance

NYSE:DHR opened at $209.14 on Monday. The firm has a market cap of $149.76 billion, a price-to-earnings ratio of 44.50, a price-to-earnings-growth ratio of 2.98 and a beta of 0.77. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company's 50-day moving average is $201.60 and its two-hundred day moving average is $197.24. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $275.51.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the prior year, the firm earned $1.72 EPS. The firm's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Danaher from $229.00 to $236.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 15th. Weiss Ratings reiterated a "hold (c-)" rating on shares of Danaher in a research report on Wednesday, October 8th. Guggenheim reiterated a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Finally, Evercore ISI boosted their price objective on shares of Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $245.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.